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ABSTRACT 
Ganoderma  lucidum,  commonly  referred  to  as  Lingzhi,  has  been  used  in  Asia  for  health 
promotion for centuries. The anti-cancer effects of G. lucidum have been demonstrated in both in 
vitro and in vivo studies. In addition, the observed anti-cancer activities of Ganoderma have 
prompted its usage by cancer patients alongside chemotherapy. 
The main two bioactive components of G. lucidum can be broadly grouped into triterpenes 
and polysaccharides. Despite triterpenes and polysaccharides being widely known as the major 
active ingredients, the different biological pathways by which they exert their anti-cancer effect 
remain poorly defined. Therefore, understanding the mechanisms of action may lead to more 
widespread use of Ganoderma as an anti-cancer agent. 
The aim of this paper is to summarise the various bioactive mechanisms that have been 
proposed  for  the  anti-cancer  properties  of  triterpenes  and  polysaccharides  extracted  from  G. 
lucidum. A literature search of published papers on NCBI with keywords “Ganoderma”  and 
“cancer”  was  performed.  Among  those,  studies  which  specifically  examined  the  anti-cancer 
activities of Ganoderma triterpenes  and polysaccharides  were selected to be included in this 
paper. 
We  have  found  five  potential  mechanisms  which  are  associated  with  the  anti-cancer 
activities  of  Ganoderma  triterpenes  and  three  potential  mechanisms  for  Ganoderma 
polysaccharides. In addition, G. lucidum has been used in combination with known anti-cancer 
agents to improve the anti-cancer efficacies. This suggests Ganoderma’s bioactive pathways may 
compliment that of anti-cancer agents.  In this  paper we present several potential anti-cancer 
mechanisms  of  Ganoderma  triterpenes  and  polysaccharides  which  can  be  used  for  the 
development of Ganoderma as an anti-cancer agent. 
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INTRODUCTION: 
Ganoderma lucidum (G. lucidum), commonly referred to as Lingzhi in China, is a fungus which 
has been widely used through the centuries for the general promotion of health and longevity in 
Asian  countries.  It  has  been  known  to  have  numerous  pharmacological  effects  including 
immuno-modulating,  anti-inflammatory,  anti-cancer,  anti-diabetic,  anti-oxidative  and  radical-
scavenging, and anti-aging effects [1]. 
Most mushrooms are 90% water by weight. For G. lucidum, the remaining 10% consists of 
26–28% carbohydrate, 3–5% crude fat, 59% crude fibre, and 7–8% crude protein [2]. In addition, 
G.  lucidum  contains  a  wide  variety  of  bioactive  constituents  such  as  terpenoids,  steroids, 
phenols,  glycoproteins,  and  polysaccharides  [3,  4].  Numerous  authors  have  shown  that 
triterpenes and polysaccharides are the major physiologically active components of G. lucidum 
[3, 4]. 
In this review, we focused on the various bioactive pathways thought to be associated with 
the anti-cancer activities of G. lucidum, in particular, the two main active ingredients: triterpenes 
and polysaccharides. 
 
Triterpenes 
Triterpenes  are  one  of  the  possible  pharmaceutically  active  compounds  contributing  to  the 
medicinal  activities  of  G.  lucidum  [5,  6].  Triterpenes  are  a  subtype  of  Terpene,  a  class  of 
naturally occurring compounds, composed of one or more isoprene units. Terpenes are widely 
distributed throughout the plant world. Many subtypes of Terpenes have been found to have anti-
inflammatory,  anti-tumourigenic,  and  hypolipidemic  activity  [7].  Triterpenes  contain  six 
isoprene units. The isoprenes may form linear chains or fold-up and form a ring-like structure. 
Ganoderic acid is a sub-type of triterpenes with four cyclic and two linear isoprenes. There are 
over 140 species of triterpenes and triterpenoids identified in G. lucidum [8]. 
Triterpenes are primarily isolated from the spores of G. lucidum and have shown remarkable 
pharmacological and therapeutic activities on multiple human diseases including cancer [5, 6]. 
Extraction of triterpenes is usually by means of methanol, ethanol, acetone, chloroform, ether, or 
a mixture of these solvents [9]. 
Studies have shown that many subtypes of triterpene extracts from G. lucidum can directly 
induce apoptosis of multiple human cancer cell lines [5]. The cytotoxic effect varied greatly 
between different subtypes of triterpenes [5]. Some subspecies of triterpenes have shown strong 
cytotoxic effects at low concentrations in various human cancer cell lines, these include: 
Ganoderic acid T is the most abundant triterpenic acid found in G. lucidum and shows 
significant anti-cancer effects in both in vitro and in vivo studies [10, 11, 12]. In a study by Chen 
et  al.  (2010),  Ganoderic  acid  T  was  shown  to  inhibit  tumour  invasion  by  inhibiting  Matrix 
Metalloproteinase (MMP)-9 expression [10]. Ganoderic acid D has been shown to directly bind 
to  14-3-3ζ  protein  in  a  study  by  Yue  et  al.  (2008),  and  this  binding  may  contribute  to  the 
apoptosis observed in HeLa cell [13]. Ganoderiol F (GA-F) is a tetracyclic triterpene found in 
Ganoderma species [14, 15]. GA-F has shown cytotoxicity in vitro against Lewis lung carcinoma 
(LLC), Meth-A, Sarcoma-180, and T-47D cell lines [15, 16]. In addition, the anti-tumour effect 
of GA-F has been demonstrated in vivo in rats implanted with LLC tumour cells [17]. Additional Functional Foods in Health and Disease 2013; 3(2):48-65                                                                    Page 50 of 65 
 
forms of triterpenes isolated from G. lucidum have shown cytotoxicity in the following human 
cancer cell lines: p388, HeLa, BEL-7402, and SGC-7901 [18, 19]. 
There are several mechanisms by which triterpenes contribute to the anti-cancer activities of 
G. lucidum as shown in Figure 1: 
 
 
 
Figure 1: An overview of anti-cancer pathways affected by the triterpenes and polysaccharides from G. 
lucidum  [*CTL  Cytotoxic  T-lymphocytes;  ECM  Extracelluar  matrix;  IL  Interleukin;  MMP  matrix 
metalloproteinase; NK Natural killer cells; PKC Protein Kinase C; ROS Reactive oxygen species; TNF 
Tumour necrosis factor; VEGF Vascular endothelial growth factor] 
 
Cell cycle arrest 
Cancer cells have a deregulated cell cycle leading to uncontrolled cell proliferation. Anti-cancer 
agents can arrest the cell cycle at G0/G1, S, or G2/M phase, reducing the rate of proliferation 
[20]. Studies have shown that triterpene extracts from G. lucidum can arrest the cell cycle at the 
G1 phase [21, 22]. The likely mechanism of action for cell cycle arrest at the G1 phase is through 
the down-regulation of Cyclin D1 via modulation of the ß-catenin pathway [23]. Cyclin D1 is a 
regulator of Cyclin Dependent Kinase (CDK) which is crucial for G1/S transition in the cell Functional Foods in Health and Disease 2013; 3(2):48-65                                                                    Page 51 of 65 
 
cycle [24]. The Cyclin D1 promoter contains transcription factor (TCF)/Lef-binding sites which 
can be activated by ß-catenin/Lef-1/TCF [25]. Approximately 30% of colon carcinoma cells 
have  an  over-expression  of  Cyclin  D1  as  a  result  of  abnormal  ß-catenin  signalling  [26]. 
Ganodermanontriol, a G. lucidum triterpene extract, inhibits proliferation of colon cancer cells 
HCT116 and HT-29 by inhibiting the expression of ß-catenin [22]. 
In addition to cell cycle arrest at the G1 phase, triterpene extracts can also inhibit cells at the 
G2/M transition [27]. Treatment with triterpene-enriched ethanol soluble fractions (WEES-G6) 
can suppress the activity of protein kinase C (PKC), leading to a prolonged G2 phase. PKC is a 
class of serine-threonine protein kinases that is selectively activated during the G2 phase of the 
cell cycle [28]. PKC is involved in the regulation of nuclear lamina disassembly during the G2 
phase [29]. Studies have shown that the use of PKC inhibitors can also cause cell cycle arrest at 
the G2 phase [30, 31]. In addition, WEES-G6 can reduce the level of Cyclin B, a kinase which is 
crucial for the transition from G2 to M phase [27]. WEES-G6 also activates c-Jun N-terminal 
kinase (JNK) and p38 kinase, both  of which are mitogen-activated protein kinases  (MAPK) 
which respond to cellular stress [27]. JNK is a critical regulator of transcription and can activate 
tumour suppressors such as  p53  [32,  33, 34]. To further support the use of triterpenes  as  a 
therapeutic  anti-cancer  agent,  Johnson  and  Lapadat.  (2002)  observed  cell  cycle  arrest  in 
triterpene-treated HuH-7 human hepatocellular carcinoma but no effect was seen in a normal 
human liver cell line [32]. In order to find the cause of the triterpene-induced G2 phase cell cycle 
arrest, Li et al. (2005) identified the inhibition of DNA synthesis via inhibition of topoisomerase 
as the likely cause of Ganoderic acid X- induced cell cycle arrest [35]. 
 
Cytotoxicity 
Cytotoxic compounds can also directly trigger apoptosis leading to programmed cell death [36, 
37].  Studies  have  shown  that  triterpenes  induce  apoptosis  in  human  cancer  cell  lines  via  a 
mitochondria-dependent pathway, followed by activation of the caspase cascade [38, 39]. 
The  intrinsic  apoptotic  pathway,  also  known  as  the  mitochondria-dependent  apoptotic 
pathway, involves decreasing the mitochondrial potential, followed by the release of cytochrome 
c from the mitochondria [40, 41].  The release of cytochrome c into the cytosol triggers the 
caspase cascade leading to apoptosis. The caspase cascade includes caspase 9 and caspase 3 
which are found to have elevated expression in human cancer cells treated with G. lucidum 
triterpenes [11, 42]. 
The release of cytochrome c from mitochondria is dependent on the permeability of the 
mitochondrial outer membrane which is closely regulated by the B-cell lymphoma 2 (Bcl-2) 
family proteins [43]. The Bcl-2 family proteins can either be pro-apoptotic or anti-apoptotic. Bcl-
2 is anti-apoptotic while Bcl-2–associated X protein (Bax) and Bcl-2-associated death promoter 
(Bad) are pro-apoptotic. The ratio of Bax/Bcl-2 balance determines the release of cytochrome c 
after apoptotic stimulus [44]. Increasing the ratio of Bax/Bcl-2 promotes apoptosis. Studies have 
shown that treatment with  G. lucidum triterpenes increases the ratio of Bax/Bcl-2 in human 
cancer  cells  by  increasing  Bax  expression  while  down-regulating  Bcl-2  expression  [42]. 
However, different subtypes of triterpenes have different effects on Bax and Bcl-2. In a study by 
Tang et al. (2006) treatment with Ganoderic acid T was shown to up-regulate Bax expression 
while Bcl-2 expression remained unchanged [11]. Functional Foods in Health and Disease 2013; 3(2):48-65                                                                    Page 52 of 65 
 
The 14-3-3 proteins are a family of conserved regulatory proteins, they are involved in many 
cellular  process  including  cell  cycle  progression  and  apoptosis  via  regulating  protein  kinase 
signalling cascades [45]. A target of 14-3-3 protein is the Bad pro-apoptotic protein. Binding of 
the  14-3-3  protein  to  Bad  inhibits  Bad-induced  cell  death  [46].  Studies  have  shown  that 
Ganoderic acids can directly bind to 14-3-3 protein thus inhibiting its activity [13, 39]. 
 
Reduced metastatic potential 
Cancer metastasis is a complex process by which cancer cells split from the primary tumour and 
invade other tissues and thereby form secondary tumours. Cancer metastasis, when left untreated, 
dramatically reduces the rate of cure and survival. There are several key proteins involved in 
cancer metastasis which may be regulated by G. lucidum triterpenes. 
Matrix Metalloproteinase is a family of proteins that degrade the extracellular matrix and 
can  promote  cancer  metastasis  [47].  Studies  showed  that  Ganoderic  acid  extracted  from  G. 
lucidum suppressed invasion of 95-D, LLC, and HCT-116 metastatic cancer cells via inhibition 
of MMP-9 expression [48, 49]. 
Interleukin (IL)-8 and other angiogenic factors such as vascular endothelial growth factor 
(VEGF) can induce angiogenesis and promote metastasis [50]. Expression of IL-8 can be up-
regulated  by  oxidative  stress  and  overexpression  of  IL-8  is  associated  with  the  metastatic 
phenotype of breast cancer cells [51, 52]. Oxidative-induced IL-8 expression was reduced in a 
breast cancer cell line after treatment with G. lucidum [53]. 
 
Anti-Inflammation 
Inflammation  has  been  linked  as  a  causal  agent  in  ~20%  of  cancers  [54,  55].  Chronic 
overexpression  of  inﬂammatory  cytokines  such  as  VEGF,  IL-6,  and  tumour  necrosis  factor 
(TNF)-α,  can  promote  carcinogenesis  [56,  57].  Dudhgaonkar  et  al.  (2009)  have  shown  that 
administration of G. lucidum triterpene extract suppressed inflammatory cytokine secretion in 
macrophage cells thus decreasing the level of inflammation [58]. 
 
Anti-oxidant 
Oxidative stress is known to be a major contributor to increased cancer risk. Free radicals and 
reactive oxygen species (ROS) are generated as by-products of metabolic processes involving 
redox enzymes and bioenergetics electron transfer, and exposure to some exogenous chemicals 
[59]. Free radicals and ROS can damage proteins and DNA within cells leading to oxidative 
stress, which can be countered by anti-oxidative enzymes and repair mechanisms. However, 
excess  oxidative  stress  can  overwhelm  the  innate  protective  systems  leading  to  a  variety  of 
physiological  disorders  including  cancer  [59].  Cancer  cells  generate  increased  levels  of  free 
radicals relative to normal cells, further contributing to cancer progression [59]. More and more 
evidence suggests that this cancer-inducing oxidative damage might be prevented or limited by 
using  anti-oxidants.  Anti-oxidants  may  mediate  their  effect  by  directly  reacting  with  ROS, 
quenching them or chelating the catalytic metal ions [60]. 
Smina et al. (2011) showed that triterpenes extracted from G. lucidum have anti-oxidative 
properties  in  vitro  and  can  reduce  oxidative  damage  by  directly  scavenging  free  radicals 
generated  in  the  cell  [61].  In  addition,  administration  of  triterpenes  to  mice  increased  the Functional Foods in Health and Disease 2013; 3(2):48-65                                                                    Page 53 of 65 
 
activities of anti-oxidant enzymes and reduced radiation-induced oxidative DNA damage in mice 
splenocytes [61, 62]. The ability of triterpenes to scavenge free radicals and enhance innate anti-
oxidant enzymes indicates that triterpenes are a highly efficient anti-oxidant. 
 
Polysaccharides 
Polysaccharides are long chain sugar molecules joined together by glycosidic bonds. Various 
types of polysaccharides, with molecular weights ranging from 4 × 10
5 to 1 × 10
6 Da have been 
identified in G. lucidum; mostly in the fruiting body and mycelia, and a few have been found in 
the spores [1].  
Structural analysis shows that polysaccharides of G. lucidum are all heteropolymers [63]. 
Glucose forms the major share of the sugar molecules; with xylose, mannose, galactose, and 
fucose in  different  conformations.  It  is  hypothesised  that the polysaccharides  extracted from 
different parts of G. lucidum induce different immune responses with varying immune potencies 
[63].  The  different  branching  conformation  and  solubility  characteristics  affects  the  anti-
tumourigenic properties of these polysaccharides [64]. β-D-glucans consisting of (1-3)-, (1-4)- 
and (1-6)-β-D linkages are known to have a stronger anti-tumour potency and better absorption 
than other polysaccharides in G. lucidum [64]. 
Together  with  the  high  concentration  of  high  molecular-weight  polysaccharides,  the 
mushroom also consists of a matrix of the polysaccharide chitin, which is largely indigestible 
and is partly responsible for the physical hardness of the mushroom [65]. 
There are three mechanisms by which Ganoderma polysaccharides exert their anti-cancer 
effect as shown in Figure 1: 
 
Improve Immune Response 
In contrast to triterpenes, numerous studies have shown that polysaccharides exert their anti-
cancer effect by enhancing the host’s immune system rather than via a direct cytotoxic effect [66, 
67, 68]. This involves the stimulation of macrophages, natural killer (NK) cells, and cytotoxic T-
lymphocytes (CTL) activities along with their secretory products like TNF, reactive nitrogen and 
oxygen intermediates, and interleukins [69]. In a study performed by Wang et al. (1997), it was 
shown that polysaccharides extracted from the fresh fruiting bodies of G. lucidum can stimulate 
the production of IL-1β, IL-6, TNF-α, and interferon-γ (IFN-γ) in human monocyte-macrophages 
and T-lymphocytes [68]. 
It  is  widely  known  that  macrophages  play  an  important  role  in  many  primary  defence 
mechanisms  via  phagocytosis  and  secretion  of  immune  cytokines  in  response  to  micro-
environmental signals [70, 71]. The G. lucidum immune-modulating substance, (a proteoglycan 
isolated from the fruiting body of G. lucidum), activate bone marrow-derived macrophages in a 
dose-dependent  manner.  These  activated  macrophages  showed  a  marked  increase  in  their 
phagocytosis activity and increased production of IL-1β and nitric oxide [72]. 
The Major Histocompatibility Complex (MHC) is a type of protein expressed on all cell 
surfaces.  The main  function of MHC  is  to  display  a molecular fraction of proteins  that  are 
formed within the cell, a process known as antigen presentation [73]. Cancer cells, which have 
abnormal proteins or changes in amount of protein expression, can be detected by immune cells 
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expression of MHC molecules to escape CTL mediated apoptosis [74]. NK cells can detect and 
induce apoptosis of cancerous cells with low MHC expression [75]. 
Fraction-3 (F3), a fucose-containing glycoprotein extracted from G. lucidum, stimulated the 
proliferation of murine spleen cells and expression of various cytokines, including IL-1, IL-2, 
and IFN-γ [76]. A study by Chien et al. (2004) showed that F3 treatment of mononuclear cells 
extracted from human umbilical cord blood stimulated their differentiation into macrophages and 
NK cells by 2.9 and 1.5 times respectively [77]. Another study showed that an F3-treated human 
acute monocytic leukemia (THP-1) cell line exhibited enhanced macrophage differentiation via 
caspases  and  p53  activation  [78].  This  differentiation  was  demonstrated  by  changes  in  cell 
adherence, cell cycle arrest, increase in the expression of differentiation markers, and down-
regulation of myeloperoxidase (MPO) [78]. The enzyme MPO is synthesized only in myeloid 
and  monocytic  cells  and  the  down-regulation  of  MPO  activity  is  a  characteristic  feature  in 
macrophage differentiation [79]. 
These  results  showed  that  polysaccharides  obtained  from  G.  lucidum  could  effectively 
increase  the  cellular  immune  activity  in-vitro  as  well  as  in-vivo,  by  modulating  cytokine 
production. 
 
Anti-oxidative Activity  
Lu  et  al.  (2001)  showed  that  dietetic  treatment  using  a  Ganoderma  mycelium-derived 
polysaccharide extract can be used to suppress the formation of colonic aberrant crypt foci in rats, 
possibly via reducing the oxidative damage induced by ROS [80, 81]. In addition, an amino-
polysaccharide fraction of G. lucidum called ‘G009’ inactivates hydroxyl radicals and superoxide 
anions and reduces DNA strand breaks in a dose-dependent manner [82]. This study showed that 
G009 inhibited the iron-induced lipid peroxidation in rat brain homogenates and showed a dose-
dependent inactivation of hydroxyl radicals and superoxide anions. It also reduced the strand 
breakage  in  DNA  caused  by  UV-induced  photolysis  in  differentiated  HL-60  (human 
promyelocytic leukaemia) cells [82]. 
 
Suppression of Angiogenesis 
Angiogenesis is a physiological process involving the development of new blood vessels from 
pre-existing  vessels.  The  normal  regulation  of  angiogenesis  is  governed  by  a  fine  balance 
between factors that induce the development of blood vessels and those that inhibit this process. 
A  disruption  of  this  balance  leads  to  pathological  angiogenesis.  Tumour  cells  are  known  to 
induce angiogenesis by secreting various growth factors such as VEGF which induce capillary 
growth into the tumour, supplying it with required nutrients and allowing for tumour expansion 
and metastasis. 
Studies have shown that G. lucidum possesses anti-angiogenic activity and can also inhibit 
the production of nitric oxide, an inducing agent of angiogenesis overexpressed in tumours [83]. 
A study by Cao et al. (2006) showed that a polysaccharide peptide (Gl-PP) isolated from G. 
lucidum inhibits the proliferation of human umbilical cord vascular endothelial cells (HUVEC) 
in a dose-dependent manner [84]. In human lung carcinoma cells, a high dose of Gl-PP for 18 
hours under hypoxic conditions led to a decrease in the amount of secreted VEGF. In HUVECs, 
Gl-PP led to a reduction in Bcl-2 expression and an increase in Bax expression which induces Functional Foods in Health and Disease 2013; 3(2):48-65                                                                    Page 55 of 65 
 
apoptosis in vascular endothelial cells. Therefore, Gl-PP may inhibit angiogenesis via inhibiting 
secretion of pro-angiogenic factors and inhibition of vascular endothelial cell proliferation [84]. 
It is possible that the cytotoxicity effect and the inhibition of proliferation observed in both 
polysaccharide and triterpene extracts may have the same bioactive pathways. 
A study by Stanley et al. (2005) found that G. lucidum prevents capillary morphogenesis, an 
important step in angiogenesis associated with the growth and progression of cancer [85]. G. 
lucidum significantly inhibited capillary morphogenesis by inhibiting the secretion of angiogenic 
factors VEGF and Transforming Growth Factor (TGF)-β1. G. lucidum was shown to inhibit 
prostate cancer angiogenesis by modulating MAPK and Protein Kinase B signalling and altering 
the phosphorylation of extracellular signal-regulated kinases 1/2 and Akt kinases [85]. 
 
Extraction Methods 
The whole spores, fruiting bodies and cultivated mycelia of G. lucidum as well as its triterpenes 
and polysaccharides extracts have been widely tested for their various anti-tumour properties. 
Different  sources  of  G.  lucidum  and  varying  extraction  procedures  to  obtain  the  required 
components have been used in various studies. The extraction process is a necessary step to 
purify  the  mushroom  by  eliminating  unnecessary  components  that  are  produced  by  the 
mushroom’s  natural  growing  process,  while  preserving  the  essential  bioactive  components 
within it. Numerous means of extraction have been developed with the objective of obtaining 
extracts with better yields and lower costs [86]. 
Generally,  most  polysaccharides  are  extracted  using  water-extract-alcohol  precipitation 
methods [87, 88]. The solubility and extraction efficiency in water depends on the molecular 
weight of the polysaccharide and water temperature, with lower molecular weight and hot water 
showing increased efficiency [89]. However, this method has its disadvantages such as reduced 
yields, long extraction time and high extraction temperature, and hence new technologies are 
being developed to overcome these drawbacks. Novel technologies using ultrasound, microwave 
and enzymatic methods have recently been developed to increase the yield in shorter extraction 
times [87]. 
Extractions using ethanol have been reported to be the easiest approach to maintain the 
activity of the triterpene extracts and to scale up its production [90]. Triterpenes are usually 
extracted using organic solvents such as methanol, ethanol, chloroform or ether followed by 
different separation methods [89]. Ultrasonic techniques are currently being used to enhance the 
rate of extraction of triterpenes by destroying the dense structure in the cells [87]. 
There are, however, very few studies comparing the different extraction procedures on the 
effectiveness  of  the  individual  bioactive  components.  However,  a  study  by  Lu  et  al.  (2004) 
examined the ethanol and water extracts from fruiting bodies and spores of the G. lucidum using 
the MTT (3-(4, 5-dimethylthiazolyl-2)-2,5-diphenyltetrazolium bromide) cell proliferation assay 
and the resulting IC50s are shown in Table 1 [91]. 
Tong  et  al  (2009)  made  a  comparison  of  the  cytotoxic  activity  induced  by  G.  lucidum 
fruiting-body extracts obtained by hot water and methanol extraction methods. Results showed 
that  methanol  extraction  produced  a  two-fold  increase  in  cytotoxic  activity  in  J558  (Balb/C 
mouse Myeloma) cells [92]. 
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Table 1: Comparison of water and ethanol extracts from G. lucidum fruiting bodies and spores. 
(adapted from [91]) 
 
Ganoderma lucidum Extract  Cell Line*  24 hours IC50 (µg/ml) 
Fruiting Body Ethanol Extract  HUC-PC  325 
Fruiting Body Water Extract  HUC-PC  1000 
Spore Ethanol Extract  HUC-PC  521 
Spore Water Extract  HUC-PC  362 
Fruiting Body Ethanol Extract  MTC-11  129.3 
Fruiting Body Water Extract  MTC-11  509 
Spore Ethanol Extract  MTC-11  274.7 
Spore Water Extract  MTC-11  365.4 
         
         *HUC-PC: human uroepithelial cell line    MTC-11: Low-grade bladder cancer cell line 
 
This shows that the organic solvent, rather than the water extraction method, has a stronger 
cytotoxic activity on cancer cells. Triterpene is the main active ingredient extracted from organic 
solvent, and polysaccharide is the main active ingredients extracted from water. This suggests 
that triterpenes may have a stronger cytotoxic effect than polysaccharides. However additional 
comparative studies using different cell lines need to be carried out to confirm these data. 
 
Ganoderma lucidum in combination with other cancer treatments  
Radiation therapy is commonly used in the treatment of cancer in order to damage the DNA of 
tumour cells, to inhibit proliferation and induce apoptosis. The main side effect of using radiation 
therapy is DNA damage to the surrounding healthy tissues. Hence, protection of non-cancerous 
tissues against radiation is vital for reducing the side effects [93].   
Many  of  the  recent  cytoprotective  agents  capable  of  protecting  normal  tissues  against 
radiation-damage  have  some  undesirable  and  serious  side  effects  that  limit  their  therapeutic 
applications [94]. However, G. lucidum has been proven to exhibit radio-protective effects in 
normal cells and enhance the recovery of cellular immune-competence from gamma–irradiation 
[95, 96].  
Chen et al. (1995) studied the effect of G. lucidum in repairing the radiation-induced damage 
in a subset of T-lymphocytes in the spleen of gamma-irradiated mice [97]. The mice were treated 
with whole body exposure to gamma-irradiation followed by administration of 400 mg/day/kg 
body weight of G. lucidum [97]. This was compared to the control, radiation-treated only mice, 
as well as radiation-treated mice administered with Krestin, a polysaccharide isolated from the 
basidomycetes of Coriolus versicolor. Results showed that after 28 days, irradiated mice treated 
with G. lucidum had the highest relative thymus weight with a greater number of CD4 and CD8 
splenocytes and an increase in leukocyte counts. This showed that G. lucidum is effective (even 
more  so  than  Coriolus  versicolor  extracts)  in  enhancing  the  recovery  of  cellular 
immunocompetence from gamma–irradiation. 
Another study, performed by Pillai et al. (2006), showed that G. lucidum prevents DNA 
damage induced by radiation. Swiss albino mice, that were exposed to gamma rays and treated 
with G. lucidum fruiting-body extracts, were evaluated for radio-protective effects [93]. Results Functional Foods in Health and Disease 2013; 3(2):48-65                                                                    Page 57 of 65 
 
showed that administration of G. lucidum extract resulted in 90% protection of plasmid DNA 
and prevented 98% of lipid peroxidation.  From this study we can conclude that G. lucidum 
protects  the  DNA  against  radiation-induced  single-strand  breaks  and  thereby  possesses 
significant radio-protective activity [93]. 
Cisplatin, the first clinical cancer chemotherapeutic agent belonging to the class of platinum-
containing anti-cancer drugs, is widely used to treat a range of tumours. However, its benefits are 
counteracted by renal impairment with a decline in glomerular filtration, which is a common side 
effect of cisplatin [98]. This nephrotoxicity has been thought to be due to the weakening of the 
renal anti-oxidant defence system. Since G. lucidum has been proven to possess in-vitro anti-
oxidant properties, a study was conducted to examine the prevention of nephrotoxicity induced 
by the anti-cancer drug cisplatin [99]. Swiss albino mice were treated with fruiting-body extracts 
of G. lucidum (250 and 500 mg/kg body weight) orally one hour before injecting cisplatin at a 
high dose (a level commonly used in clinical practice and found to produce nephrotoxicity and 
cytotoxicity) [99, 100]. Nephrotoxicity was measured by determining the serum creatinine and 
urea levels  and renal  anti-oxidant  status  and results  showed that it significantly reduced the 
elevated  serum  creatinine  and  urea  levels  [99].  Renal  anti-oxidant  defence  system  (such  as 
superoxide dismutase, catalase, glutathione peroxidase activities and reduced glutathione) levels 
following treatment with cisplatin were restored to normal and the therapeutic effects of cisplatin 
were retained [99]. 
These studies show that G. lucidum aids in the reduction of toxicities resulting from various 
popular modes of cancer treatment and could therefore play a major role in combination therapy 
for cancer treatments. 
 
CONCLUSION: 
Ganderma lucidum has been widely used through the centuries for numerous pharmacological 
benefits,  including  immuno-modulating,  anti-inflammatory,  anti-cancer,  anti-diabetic,  anti-
oxidative, and radical-scavenging, and anti-aging effects and only in the past two decades has 
scientific information become available that supports some of these claims. The potency of G. 
lucidum depends chiefly on its chemical constituents, namely the triterpenes and polysaccharides 
that  make  up  the  fruiting  body,  mycelium  or  spores.  Its  anti-cancer  properties  have  been 
demonstrated  in  various  human  and  murine  cancer  cell  lines.  However,  the  mechanisms 
responsible for the anti-cancer effects of G. lucidum on cancer cells remain inconclusive. This 
review paper has identified five potential mechanisms associated with the anti-cancer activities 
of triterpenes and three for polysaccharides. 
Triterpenes have been shown to  induce cell cycle arrest at  the  G1 phase by the down-
regulation of Cyclin D1, and at the G2 phase by suppressing the activity of PKC. It also induced 
apoptosis in cancer cell lines via mitochondria-dependent pathways followed by activation of the 
caspase cascade. Triterpenes also prevented tumour metastasis by regulating MMP and IL-8 and 
suppressed inflammatory cytokine secretion in macrophage cells. Lastly, triterpenes were found 
to act as an anti-oxidant by scavenging free radicals and enhancing innate anti-oxidant enzymes. 
Polysaccharides have been shown to enhance the host’s immune response by stimulating the 
production of macrophages, NK cells, and T-lymphocytes. Like triterpenes, polysaccharides can 
act  as an  anti-oxidant by  reducing oxidative damage induced by ROS  and preventing DNA Functional Foods in Health and Disease 2013; 3(2):48-65                                                                    Page 58 of 65 
 
strand  breaks.  It  also  prevents  tumour-derived  angiogenesis  by  reducing  the  proliferation  of 
HUVEC and by inhibiting the secretion of angiogenic factors such as VEGF and TGF-β1. 
In  conclusion, G. lucidum may represent  a practical  and promising approach for cancer 
prevention and cancer treatment based on current available data from in vitro and in vivo studies. 
However, further experimental, epidemiological, and clinical studies need to be carried out to 
identify other molecular targets; resolve the relationships between G. lucidum intake and cancer 
risks;  and  explore  the  optimum  dosing,  efficacy,  and  safety  alone  and  in  combination  with 
chemotherapy/radiotherapy. In addition to the anti-cancer activity, G. lucidum has been used for 
the general promotion of health and longevity. The anti-inflammatory and immune-promoting 
effects described in this review can potentially facilitate the treatments of other diseases such as 
arthritis, HIV, and Crohn's disease [1, 101]. 
 
 
 
List of Abbreviations Used: 
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Bax  Bcl-2–associated X protein  
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CDK  Cyclin Dependent Kinase 
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G. lucidum      Ganoderma lucidum 
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HUVEC  Human umbilical cord vascular endothelial cells 
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IL  Interleukin 
JNK  c-Jun N-terminal kinase 
LLC  Lewis lung carcinoma 
MAPK  mitogen-activated protein kinases 
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